Literature DB >> 1782081

Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador).

E Kovacs1, T Hajto, K Hostanska.   

Abstract

We investigated alteration in DNA repair during therapy with an immunomodulator. 14 patients with advanced breast cancer were treated parenterally with Iscador, an extract of Viscum album (mistletoe). As a parameter for measurement of DNA repair the incorporation of (3H) thymidine into DNA of unstimulated lymphocytes after ultra violet light (UV) damage was taken. The DNA repair values in the patients were very low before treatment and on day 1: on average 16% of those in a healthy control population. Values started to increase on day 2 and on days 7-9 were on average 2.7 times higher than before treatment. 12/14 patients showed an improvement in repair. The values of spontaneous DNA synthesis were not altered during the treatment. We suggest that the increase of DNA repair could be due to a stimulation of repair enzymes by lymphokines or cytokines secreted by activated leukocytes or an alteration in the susceptibility to exogenic agents resulting in less damage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782081     DOI: 10.1016/0277-5379(91)90443-h

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

Review 1.  Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative.

Authors:  E Kaegi
Journal:  CMAJ       Date:  1998-05-05       Impact factor: 8.262

2.  Do chemo- and radiotherapy affect the DNA repair ability of lymphocytes?

Authors:  E Kovacs; H Langemann; H Ludwig
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

3.  Biochemical, histochemical and cell biological investigations on the actions of mistletoe lectins I, II and III with human breast cancer cell lines.

Authors:  U Schumacher; A Stamouli; E Adam; M Peddie; U Pfüller
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

4.  Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications.

Authors:  Tibor Hajtó; Katarina Hostanska; Timea Berki; László Pálinkás; Ferenc Boldizsár; Péter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2005-01-28       Impact factor: 2.629

5.  Evaluation of Preclinical Assays to Investigate an Anthroposophic Pharmaceutical Process Applied to Mistletoe (Viscum album L.) Extracts.

Authors:  Stephan Baumgartner; Heidi Flückiger; Matthias Kunz; Claudia Scherr; Konrad Urech
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-04       Impact factor: 2.629

6.  Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients.

Authors:  Anja Thronicke; Shiao Li Oei; Antje Merkle; Harald Matthes; Friedemann Schad
Journal:  Medicines (Basel)       Date:  2018-09-06

7.  Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL).

Authors:  Kathrin Wode; Johanna Hök Nordberg; Gunver S Kienle; Nils O Elander; Britt-Marie Bernhardson; Berit Sunde; Lena Sharp; Roger Henriksson; Per Fransson
Journal:  Trials       Date:  2020-09-11       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.